2015 | Innocoll Pharmaceuticals

Date

Title

Dec 17, 2015

Innocoll AG Appoints Charles Katzer as Head of Manufacturing and Technical Operations

Dec 09, 2015

Innocoll AG Announces Plan to Move Corporate Domicile to Ireland

Nov 11, 2015

Innocoll AG Announces Third Quarter 2015 Financial and Operating Results and Corporate Update

Nov 04, 2015

Innocoll to Report Third Quarter 2015 Financial Results and Host Webcast and Conference Call on November 11, 2015

Sep 16, 2015

Innocoll AG Announces First Patient Dosed in the XaraColl MATRIX-2 Phase 3 Study for the Treatment of Postoperative Pain

Sep 14, 2015

Innocoll AG Announces Departure of Chief Medical Officer

Sep 02, 2015

Innocoll AG Announces First Patient Dosed in the XaraColl MATRIX-1 Phase 3 Study for the Treatment of Postoperative Pain

Aug 14, 2015

Innocoll AG Announces Second Quarter 2015 Financial and Operating Results and Updates Late-Stage Product Portfolio Progress

Aug 13, 2015

Innocoll AG Appoints Rich Fante as Chief Commercial Officer and Head of Business Development

Aug 07, 2015

Innocoll to Report Second Quarter 2015 Financial Results and Host Webcast and Conference Call on August 14, 2015

Jul 01, 2015

Innocoll AG Appoints Jose Carmona as Chief Financial Officer

Jun 30, 2015

Innocoll AG Announces Qualified Infectious Disease Product (QIDP) Designation for Cogenzia for the Adjunctive Treatment of Moderate and Severe Diabetic Foot Infection

Jun 17, 2015

Innocoll AG to Present at JMP Securities Healthcare Conference

Jun 15, 2015

Innocoll AG Announces First Patient Dosed in the Cogenzia COACT-2 Phase 3 Study for the Treatment of Diabetic Foot Infection

May 15, 2015

Innocoll AG Announces First Patient Dosed in the Cogenzia COACT-1 Phase 3 Study for the Treatment of Diabetic Foot Infection

May 14, 2015

Innocoll AG Announces First Quarter Financial and Operating Results

May 07, 2015

Innocoll to Report First Quarter 2015 Financial Results and Host Webcast and Conference Call on May 14, 2015

Apr 24, 2015

Innocoll AG Announces Pricing of Follow-On Offering

Apr 01, 2015

Pivotal Pharmacokinetic Study of Innocoll’s XaraColl(R) Supports Use of 300 mg Dose for Phase 3 Clinical Studies in Post-Operative Pain

Mar 30, 2015

Innocoll AG Secures EUR 25 Million Loan Commitment From European Investment Bank (EIB)

Mar 19, 2015

Innocoll AG Announces Fourth Quarter and Full Year 2014 Financial and Operating Results

Mar 18, 2015

Innocoll AG Appoints James Tursi, M.D., as Chief Medical Officer

Mar 13, 2015

News